Tscan Therapeutics (NASDAQ: TCRX) — Company Overview, News & Financial Data
Tscan Therapeutics develops T-cell receptor therapies to treat cancer through proprietary technology.
Tscan Therapeutics
Tscan Therapeutics (NASDAQ:TCRX) is a biotechnology firm focused on the innovation and development of T-cell receptor (TCR)-engineered T cell therapies for the treatment of patients with cancer. Its operations are mainly centered around the research, development, and commercialization of its proprietary TCR-T cell therapy platform, which aims to identify and harness the power of immune cells to fight cancer more effectively. The company's projects include a diverse pipeline of TCR-T therapies targeting both solid tumors and hematologic malignancies. Objectives of Tscan Therapeutics are to advance these therapies through clinical trials, achieve regulatory approvals, and ultimately, deliver new and effective cancer treatments to patients in need.
Snapshot
Operations
Products and/or services of Tscan Therapeutics
- A unique platform for discovering T cell receptors (TCRs) targeting both solid tumors and hematological cancers, aiming to advance cancer immunotherapy.
- Development of TSC-100, a therapy aimed at treating hematologic cancers, specifically leveraging donor-derived T cells to target leukemic cells post-transplant.
- TSC-101, a proprietary T cell therapy targeting relapsed or refractory hematological malignancies, designed to boost patient immune systems and combat cancer more effectively.
- A comprehensive diagnostic tool that identifies patient-specific TCR targets, aiding in the customization of immunotherapy treatments.
- Collaboration on a research project focused on enhancing the specificity and efficacy of T cell therapies for solid tumors, aiming to increase treatment success rates.
- Investment in advanced manufacturing processes for T cell therapies, ensuring scalable, cost-effective, and timely delivery of treatments to patients.
Tscan Therapeutics executive team
- Gavin MacBeathCEO, Principal Financial Officer, Principal Accounting Officer & Director
- Stephen J. ElledgeCo-Founder & Chairman of Scientific Advisory Board
- Tomasz KulaCo-Founder & Member of Advisory Board
- Zoran ZdraveskiChief Legal & Strategy Officer and Company Secretary
- Ann HargravesChief Human Resources Officer
- Shrikanta ChattopadhyaySenior VP & Head of Translational Medicine
- Jim MurrayChief Development Operations Officer
- Cagan GurerSenior Vice President of Discovery
Latest news about Tscan Therapeutics
Key financials
Reported results for Tscan Therapeutics, in USD.
- Market cap
- 12.8M
- Revenue (TTM)
- 7.1M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.9
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 10.3M | -135.8M | -129.8M | |
| 2.8M | -134.8M | -127.5M | |
| 21M | -93.5M | -89.2M | |
| 13.5M | -66.6M | -66.2M |